Asieris Pharmaceuticals Signed Licensing Deal with Theramex
The agreement grants Theramex rights to market the cervical precancer treatment CEVIRA in several international regions.
Updated on Oct. 7, 2026 in Biotech
Live Poll
Do you believe pharmaceutical licensing deals generally benefit patients in your country?
Asieris Pharmaceuticals has entered an exclusive licensing agreement with Theramex to distribute the photodynamic drug-device combination product CEVIRA. The partnership covers territories including Europe, Australia, New Zealand, and Turkey.
Why it matters
This collaboration is expected to accelerate the global commercialization of CEVIRA, a non-invasive treatment for cervical precancerous lesions. The deal combines Asieris's drug development with Theramex's established market presence in over 50 countries.
CEVIRA is a photodynamic drug-device combination product that treats cervical precancerous lesions non-invasively. The therapy received approval from China's National Medical Products Administration in March 2026.
The players
Asieris Pharmaceuticals
A biopharmaceutical company founded in 2010 that specializes in developing non-invasive treatments for genitourinary diseases.
Theramex
A global specialty pharmaceutical company headquartered in London that focuses on products for women's health.
The details
Under the terms of the deal, Theramex assumes exclusive rights to commercialize the product across its licensed territories. Asieris retains full rights to the therapy for all other markets globally while awaiting further regulatory clarity for the device in Europe.
Timeline
Asieris Pharmaceuticals was founded in March 2010.
China approved CEVIRA as a non-invasive therapy in March 2026.
Asieris and Theramex entered the licensing agreement on October 7, 2026.
The Tech Race
The drug's approval by the Chinese National Medical Products Administration framework marks a significant milestone in its path toward broader global clinical adoption. This agreement transitions the technology from a regionally approved therapy to a platform intended for international scale.
Patients may eventually see wider availability of this non-invasive treatment option in their home regions as Theramex proceeds with commercialization. Access remains subject to regional regulatory milestones and the completion of necessary manufacturing and supply audits.
The takeaway
This partnership highlights the trend of regional biotech firms leveraging the distribution networks of established international pharmaceutical companies to scale novel therapies. It also underscores the importance of regional regulatory assessments in determining the speed of global drug access.
Further reading
For more on the latest trends in the sector, visit the Biotech section.
Live Poll
Do you believe pharmaceutical licensing deals generally benefit patients in your country?
